- Home
- PIM vs SGHT Comparison
PIM vs SGHT Comparison
Compare PIM & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIM
- SGHT
- Stock Information
- Founded
- PIM 1988
- SGHT 2011
- Country
- PIM United States
- SGHT United States
- Employees
- PIM N/A
- SGHT N/A
- Industry
- PIM Finance Companies
- SGHT Medical Specialities
- Sector
- PIM Finance
- SGHT Health Care
- Exchange
- PIM Nasdaq
- SGHT Nasdaq
- Market Cap
- PIM 161.4M
- SGHT 140.1M
- IPO Year
- PIM N/A
- SGHT 2021
- Fundamental
- Price
- PIM $3.35
- SGHT $3.03
- Analyst Decision
- PIM
- SGHT Buy
- Analyst Count
- PIM 0
- SGHT 7
- Target Price
- PIM N/A
- SGHT $3.92
- AVG Volume (30 Days)
- PIM 57.5K
- SGHT 161.2K
- Earning Date
- PIM 01-01-0001
- SGHT 05-08-2025
- Dividend Yield
- PIM 8.28%
- SGHT N/A
- EPS Growth
- PIM N/A
- SGHT N/A
- EPS
- PIM 0.05
- SGHT N/A
- Revenue
- PIM N/A
- SGHT $78,109,000.00
- Revenue This Year
- PIM N/A
- SGHT N/A
- Revenue Next Year
- PIM N/A
- SGHT $11.17
- P/E Ratio
- PIM $63.80
- SGHT N/A
- Revenue Growth
- PIM N/A
- SGHT N/A
- 52 Week Low
- PIM $2.90
- SGHT $2.03
- 52 Week High
- PIM $3.28
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- PIM 62.75
- SGHT 56.13
- Support Level
- PIM $3.28
- SGHT $2.81
- Resistance Level
- PIM $3.32
- SGHT $3.26
- Average True Range (ATR)
- PIM 0.03
- SGHT 0.24
- MACD
- PIM 0.01
- SGHT -0.01
- Stochastic Oscillator
- PIM 100.00
- SGHT 38.57
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.